**Name of Journal: *World Journal of Radiology***

**ESPS Manuscript NO: 21817**

**Manuscript Type: ORIGINAL ARTICLE**

***Retrospective Study***

**Correlation between thoracic aorta 18F-natrium fluoride uptake and cardiovascular risk**

Fiz F *et al.* Vascular NaF uptake and cardiovascular risk

**Francesco Fiz, Silvia Morbelli, Matteo Bauckneht, Arnoldo Piccardo, Giulia Ferrarazzo, Alberto Nieri, Nathan Artom, Manlio Cabria, Cecilia Marini, Marco Canepa, Gianmario Sambuceti**

**Francesco Fiz, Silvia Morbelli, Matteo Bauckneht, Giulia Ferrarazzo, Alberto Nieri, Gianmario Sambuceti,** Nuclear Medicine, Department of Health Science, University of Genoa and IRCCS San Martino-IST, 16132 Genoa, Italy

**Arnoldo Piccardo, Manlio Cabria,** Nuclear Medicine Unit, Galliera Hospital, Mura delle Cappuccine 14, 16128 Genoa, Italy

**Nathan Artom**, Clinic of Internal Medicine 1, Department of Internal Medicine, University of Genoa School of Medicine, 16132 Genoa, Italy

**Cecilia Marini,** CNR Institute of Molecular Bioimaging and Physiology Milan, section of Genoa, c/o Nuclear Medicine, 16132 Genoa, Italy

**Marco Canepa,** Cardiovascular Unit, Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy

**Author contributions:** Morbelli S and Fiz F designed the study; Nieri A, Ferrarazzo G Arthom N, Bauckneht M and Morbelli S performed the VOI on the PET/CT images; Fiz F performed the retrospective analysis of PET/CT images data, literature search and drafted the manuscript; Bauckneht M and Ferrarazzo G drafted figures of the paper; Morbelli S, Sambuceti G, Canepa M, Marini C, Piccardo A and Cambria M made critical revisions related to important intellectual content of the manuscript; Morbelli S and Fiz F have given final approval of the version of the article to be published; all authors read and approved the final manuscript.

**Institutional review board statement:** The Internal Review Board (Comitato Etico Regionale della Liguria) evaluated and approved this retrospective study.

**Informed consent statement:** Each patient, or their legal guardian, provided written informed consent. Images and data were anonymized before data analysis.

**Conflict-of-interest statement:** The authors have no conflict of interest to declare.

**Data sharing statement:** Statistical code and dataset are available from the corresponding author at his email address. All data are anonymized and there is no risk of patients’ identification.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to:** **Francesco Fiz, MD,** Nuclear Medicine, Department of Health Science, University of Genoa and IRCCS San Martino-IST, Largo R. Benzi 10,16132 Genoa, Italy**.** francesco.fiz.nm@gmail.com

**Telephone**: +39-1-5552027

**Received:** July 29, 2015

**Peer-review started:** July 31, 2015

**First decision:** November 6, 2015

**Revised:** November 24, 2015

**Accepted:** December 13, 2015

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To investigating the relationship between thoracic and cardiac 18F-Natrium-Fluoride (NaF) uptake, as a marker of ongoing calcification and cardiovascular risk factors.

**METHODS:** Seventy-eight patients (44 females, mean age 63, range 44-83) underwent whole body NaF PET/CT. Cardiovascular risk (CVR) was used to divide these patients in three categories: low (LR), medium (MR) and high risk (HR). NaF uptake was measured by manually drawing volumes of interest on the ascending aorta, on the aortic arch, on the descending aorta and on the myocardium; average standardized uptake value was normalized for blood-pool, to obtain target-to-background ratio (TBR). Values from the three aortic segments were then averaged to obtain an index of the whole thoracic aorta.

**RESULTS:** A significant difference in whole thoracic aorta TBR was detected between HR and LR (1.84 ± 0.76 *vs* 1.07 ± 0.3, *P* < 0.001), but also between MR and HR-LR (1.4 ± 0.4, *P* < 0.02 and *P* < 0.01, respectively). Significance of this TBR stratification strongly varied among thoracic aorta subsegments and the lowest P values were reached in the descending aorta (*P* < 0.01). Myocardial uptake provided an effective CVR classes stratification (*P* < 0.001).Correlation between TBR and CVR was appreciable when the whole thoracic aorta was considered (R = 0.67), but it peaked when correlating the descending thoracic segment (R = 0.75), in comparison with the aortic arch and the ascending segment (R = 0.55 and 0.53, respectively).

**CONCLUSION:** Fluoride uptake within the thoracic aorta wall effectively depicts patients' risk class and correlates with cardiovascular risk. Descending aorta is the most effective in CVR determination.

**Key words**: 18F-Natrium fluoride; Plaque imaging; PET/CT; Cardiovascular risk profile; Thoracic aorta

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: We evaluated, in 78 patients who underwent whole body 18F-Natrium Fluoride (NaF) PET/CT, the NaFuptake in different segments of thoracic aorta and within the myocardium, as a measure of ongoing molecular calcification. In particular, we tested the hypothesis of a correlation between thoracic aorta uptake and cardiovascular risk (CVR). We thus assessed NaF uptake (TBR) in different CVR groups (high, medium and low) and its correlation with absolute CVR value. TBR stratified the three CVR classes, mostly in the descending aortic segment and in the myocardium. Thoracic aorta uptake correlated with CVR and with myocardial uptake.

Fiz F, Morbelli S, Bauckneht M, Piccardo A, Ferrarazzo G, Nieri A, Artom N, Cabria M, Marini C, Canepa M, Sambuceti G. Correlation between thoracic aorta 18F-natrium fluoride uptake and cardiovascular risk. *World J Radiol* 2015; In press

**INTRODUCTION**

Cardiovascular disease has been representing, for many decades an ever-ongoing pandemia; acute and chronic cardiovascular ailments, once a hallmark of western population and lifestyle, have seeped through the lower-income population strata[1]. The assessment of individual cardiovascular risk (CVR) allows the implementation of primary and secondary prevention measures[2-4], such as lifestyle modifications and the[5].

However, CVR assessment does not provide any information on atherosclerotic plaque biology and progression; it neither can effectively tell whether vascular lesions are stabilized by therapy nor can identify those vascular segments that are at higher risk for occlusion.

To overcome this limitation, non-invasive imaging has been proposed. The most widespread application is coronary calcium scoring (CS), which uses the high attenuation coefficient of calcium to detect calcified plaques within the vascular tree by X-ray computed tomography (CT)[6]. This technique is able to thoroughly depict the total coronary calcification load, which is an expression of the underlying plaque burden; it is however unclear whether data provided by this type of imaging are able to accurately stratify the actual CVR[7-9].

Discrepancies between CS and CVR are often related to the relatively low sensitivity of the CT approach, which is unable to detect micro-calcifications[10] and thus tend to miss the earlier phases of plaque formation, which would probably benefit the most from clinical intervention. In addition, tomo-densitometric approaches are unable to reveal whether the plaque is at risk of rupture.

In order to overcome these limitations, radio-isotope plaque imaging was proposed in relatively recent times[8,11-14]. In particular, the use of bone-seeking positron-emitting tracer, such as 18F-Natrium Fluoride (18F-NaF) was attempted, given the great similarity in actors participating to bone apposition in the skeleton and plaque calcification in the arterial wall[15]. These studies confirmed the feasibility of 18F-NaF plaque imaging and the correlation of arterial 18F-NaF uptake with CVR[8]. Recent evidence points out that this approach is mostly helpful in the earlier phases of calcification, while the plaque is still actively concentrating mineral ions[16]. Moreover, 18F-NaF plaque imaging has shown potential even in the identification of the vulnerable plaque[17,18].

These considerations should theoretically bolster the application of 18F-NaF imaging in the coronary district. However, this type of approach is still limited by several PET-related factors, such as the low spatial resolution and the continuous cardiac movement, which prevent an accurate depiction of coronary wall mineral metabolism and causes high variability in the evaluated uptake[14].

These issues can be overridden in at least two ways. First, there is strong evidence that thoracic aorta calcifications are strongly linked with coronary artery calcifications score[19,20]; moreover, aortic lesions have been shown to even precede those in the epicardial arteries[21]. Thus, processes underlying thoracic aorta mineral turnover could herald or mirror those observed in the coronary tree.

Alternatively, cardiac fluoride deposition could be measured on the entire myocardium, as proposed by Beheshti *et al*[22], thus including in the semi-quantitative analysis both the contribution from major vessels and the signal from the microvasculature. This approach could limit the impact of smear artifacts due to cardiac motion and small vessel diameter.

In the present study, we analyze the correlation between clinical CVR score and two indexes of thoracic aorta and global cardiac 18F-NaF uptake, aiming to test the feasibility of their use as surrogate markers of CVR.

**MATERIALS AND METHODS**

***Patients population***

The study included 78 patients with either breast or prostate cancer (44 females, mean age 63.3 ± 8.2 range 44-83) undergoing 18F-NaF PET/CT scan for evaluation of presence of bone metastases. Exclusion criteria included history of major cardiac adverse events, vasculitis, autoimmune or systemic inflammatory disease or chemotherapy in the preceding 8 wk, as previously proposed[8]. Cardiovascular risk stratification was performed according to a simplified version of the Framingham model (including Age, Diabetes, Smoking, Systolic Blood Pressure and BMI)[4]. According to the Framingham score, the whole study group was subdivided into three risk categories: high (> 20%), intermediate (10% - 20%) and low (< 10%) risk of cardiovascular events in the next 10 years.

Ongoing or previous treatment with statins was used as a further exclusion criterion to avoid influence of this treatment on the results[5]. The Internal Review Board evaluated and approved this retrospective study; all patients signed a written informed consent.

***18F-NaF PET acquisition and reconstruction***

Patients underwent 18F-NaF PET/CT using two 16 slices PET/CT hybrid systems: (1) biograph 16 (Siemens Medical Solutions, Knoxville TN, United States); (2) discovery LS (GE Medical Systems, Milwaukee, WI, United States). In both cases patients received an intravenous bolus injection of 18F-NaF (4.8-5.2 MBq per kilogram of body weight). PET/CT acquisition started 60-75 min thereafter, in the meantime the patient was hydrated and encouraged to void, as to diminish the unbound tracer fraction. The entire body was scanned from vertex to toes in an “arms down” position; emission scan lasted 120’’ per bed position. PET raw data were reconstructed by means of ordered subset expectation maximization (OSEM, 3 iterations, 16 subsets) and attenuation correction was performed using CT data. The transaxial field of view and pixel size of the reconstructed PET images were 58.5 cm and 4.57 mm, respectively, with a matrix size of 128×128. As per standard PET/CT imaging protocol, 16-detector row helical CT scan was performed with non-diagnostic current and voltage settings (120 Kv, 80 mA), with a gantry rotation speed of 0.5 s and table speed of 24 mm per gantry rotation. No contrast medium was injected. The entire CT dataset was fused with the 3-dimensional PET images using an integrated software interface (Syngo; Siemens Erlangen, Germany) and was used for anatomical localization.

***Image analysis***

Reconstructed images were anonymized and analyzed offline on a dedicated workstation, running a DICOM image visualizer (Osirix 64-bit, Pixmeo, Geneva, CH). Volume of interest (VOI) were manually drawn on three segments of the thoracic aorta (ascending, arch, descending) using the co-registered CT images as anatomical reference and on the entire myocardium, as proposed by Beheshti *et al*[22]. The three aortic segments were averaged to obtain the overall thoracic aorta uptake. See Figure 1 for an example of VOI generation. Average standardized uptake value (SUV) was calculated and then normalized for background activity, obtained as mean SUV of a 10-slice thick VOI drawn on the inferior vena cava. Resulting figure was labeled target-to-background ratio (TBR); myocardial uptake was defined Normalized Global Molecular Calcification Score (NGMCS), as proposed[22].

***Statistical analysis***

All data are reported as mean ± SD. Differences between groups were tested using one-way analysis of variance, with intergroup comparison afforded using Bonferroni test. Two-tailed Pearson R index was used to test the significance of correlations. Intra- and inter-rater agreement were afforded using Cohen’s kappa and two-tailed Pearson R for qualitative and quantitative variables, respectively. Statistical analyses were performed using a software application (SPSS, v. 21.0, IBM, Armonk NY, United States). The statistical review of the manuscript was performed by a biomedical statistician.

**RESULTS**

***Patients population***

After stratification, 20, 36 and 22 patients belonged to the high, medium and low risk category, respectively. Mean ten-years CV risk was 29±2.4% for the high-risk population, 14.3 ± 3 for the medium risk stratum and 6.6 ± 2.3 for the low risk group. The latter patients were also significantly younger with respect to the other two sub-populations (58.3 ± 8.2 *vs* 65 ± 9.5 – medium risk and 65 ± 9.1 – high risk) (Table 1).

***CV risk stratification***

TBR effectively stratified the three risk categories, when considering the overall thoracic aorta (1.8 ± 0.75, 1.4 ± 0.4 and 1.14 ± 0.34 for high, medium and low risk, respectively, *P* < 0.05).

Significance of stratification varied among aortic subsegments, with descending being capable to tell apart the three CVR cathegories (TBR equal to 1.94 ± 0.8, 1.44 ± 0.45 and 1.14 ± 0.34, respectively, *P* < 0.02). Conversely, aortic arch and ascending aorta could discriminate high and low risk (*P* < 0.01 and *P* < 0.02) but provided less clear distinction between medium risk and the other two risk categories. Refer to Figure 2 and to Table 2 for the exact figures of TBR and significance.

NGMCS, resulted an effective index of risk assessment: its values were 104 ± 45.6, 62 ± 20.8 and 42.7 ± 17.4 in high, medium and low CV risk groups, respectively (*P* < 0.001; Table 2 and Figure 2).

***Correlation between aortica NaF uptake, CV risk and NGMCS***

Overall, thoracic aorta TBR showed a significant correlation with CVR (R = 0.82, *P* < 0.001). Among segments, descending aorta displayed the closest correspondence to the clinical risk assessment (R = 0.79). Among single risk factors, age and hypertension were tightly associated with aortic TBR (R = 0.32, *P* < 0.05; R = 0.54, *P* < 0.01, respectively); moreover, patients with diabetes had a significantly higher TBR with respect to non-diabetics (1.7 ± 0.7 and 1.4 ± 0.5, *P* < 0.01).

Aortic TBR showed a significant correlation with NGMCS as well (whole thoracic aorta *vs* NGMCS produced an R-index of 0.67). However, this correlation was prevalently observed in descending aorta (R = 0.72) (Table 3 and Figure 3).

Finally, measurement of TBR was accurate and relatively operator-independent: intra- and inter-rater agreement was excellent (Cohen’s kappa value = 0.91; Pearson’s R = 0.95).

**DISCUSSION**

In recent years, non-invasive, functional imaging of the coronary district has received a large attention[17]. In particular, the widespread distribution of PET scanner with 3D detection technology has allowed grasping the signal produced by plaque metabolism[11-14,16]. The scientific background underlying this approach is still relatively young and its applications lie predominantly within the research terrain[23]. However, a few studies have provided a glimpse of future clinical application: the two main streaks are at present the detection of early (CT-negative) arterial plaque[16,22,24] and the identification of the vulnerable atherosclerotic lesion[18,26].

Although the issue of organ movement can be solved by gating[18], the main limiting factor in applying PET imaging on the study of the coronary district is the small size of these vessels[26], which fall below the resolution capability of most scanner[27] and can cause underestimation of PET signal due to partial volume effect.

In this context, the utilization of surrogate measures to estimate the coronary mineral turnover can provide an affordable method to interrogate calcium deposition in this district; our data show a tight correlation between activity of thoracic aorta, activity within the myocardium, depicting the process of arterial calcification as a systemic ailment, rather than a localized phenomenon. The concept of “plaque promoting environment” is further corroborated in the analysis of the whole myocardial volume: the application of the model by Beheshti *et al*[22], with subsequent normalization for background activity, provided an excellent stratification among risk classes. The evidence of increased macro and micro-vascular signal from high-risk patients opens new questions, which call for longitudinal studies, aimed to assess whether an increased NaF activity is the harbinger of future calcifications and/or adverse cardiovascular events.

Correlation between aortic uptake and CV risk was consistent in all three segments but relationship between thoracic and cardiac 18F-NaF accumulation was somewhat less steady and prevailed in the arch and in descending aorta. This is in agreement with our previous observation, which demonstrated that vessel fluoride uptake is “per se” a marker of CVR, regardless of the studied segment[8]. Conversely, intensity of this uptake tends to correlate in vessels that are subject to similar flow conditions. Specifically, these data parallel those reported in the literature for vascular calcification indicating that vascular regions characterized by vessel branching are more prone to plaque formation, due to the influence of regional flow alterations[28,29]. These considerations imply that, when using thoracic aorta as a surrogate for coronary artery vascular lesions, the analysis should be focused on the descending segment and on the arch.

This study presents some limitations. It is a retrospective study, performed on patients that were referred for an oncologic condition. Ethical consideration impeded radiotracer injection outside of validated clinical indications; recent studies have yet presented strong evidence that vascular and plaque NaF uptake is linked with active calcification processes[18,30]. Moreover, the strict inclusion criteria limited the size of the population; however, the sample size actually matched the one of several previous studies regarding NaF uptake within plaque and arterial vessels[10,14,18].

 Finally, cardiac volume-of-interest was placed on an ungated PET; however, the large volume of the sampled tissue should have largely limited the influence of motion artifacts.

Altogether, the continuous improvement of PET/CT instrumentation has been opening a whole new perspective on plaque biology. The systematization of this analysis has the potential to allow the quantification of plaque mineral turnover, granting the possibility to stratify the evolutionary pattern of vascular lesions. In the coronary artery setting, where the small vessel size remains at the boundary of the PET diagnostic capability, the application of an indirect evaluation of active calcification might enable to derive a prognostic index and to measure the effectiveness of plaque treatments.

**COMMENTS**

***Background***

18F-Natrium-Fluoride (NaF) is a bone seeking tracer that has been successfully proposed for the imaging of micro-calcification processes within the atherosclerotic plaque. Since coronary arteries are one of the most important targets of this kind of research, but tend to be subject to partial volume effects in images produced by commercial scanners. We hypothesized that thoraci aorta could serve as an ersatz, on the bases of the known correlation between thoracic aorta and coronary calcifications.

***Research frontiers***

The analysis proved that thoracic aorta uptake is related to both the cardiovascular risk profile and the uptake in the whole myocardium (as a measure of the entire calcification activity occurring in the heart micro- and macro-vasculature).

***Innovation and breakthrough***

Computational analysis of NaF uptake within the thoracic aorta vessel walls has the potential to become a robust, independent and non-invasive risk of cardiovascular risk. Differently from clinical scores, which give off a likelihood of acute events, NaF uptake actually depicts the activity of calcium deposition within arteries, as a marker of plaque growth.

***Applications***

This research should serve as a base to further perspective studies, used to identify the role of NaF uptake in predicting future CV events. This kind of analysis could be automated by applying simple mathematical approaches, so as to become faster and more operator-independent.

***Peer-review***

“The Authors present a retrospective analysis of correlation between different segments of thoracic aorta 18F-NaF uptake and cardiovascular risk, as well as to evaluation of correspondence between aortic and myocardial uptake in 78 oncologic patients. The study is interesting, even if there are several reports demonstrating the reliability of 18F-NaF PET/TC in imaging plaque inflammation in large arteries and the correlation between radiotracer uptake in atherosclerotic lesions and the presence of cardiovascular risk factors, identifying the patients at risk of future cardiovascular events”.

**REFERENCES**

1 **World Health Organization.** "Top ten causes of death. 2012. Fact sheet N310: 3. [updated 2014 May]. Available from: URL: http://www.who.int/mediacentre/factsheets/fs310/en/

2 **Kannel WB**, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. *Am J Cardiol* 1976; **38**: 46-51 [PMID: 132862]

3 **Greenland P**, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, Smith SC, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Nishimura R, Ohman EM, Page RL, Stevenson WG, Tarkington LG, Yancy CW. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2010; **56**: e50-103 [PMID: 21144964 DOI: 10.1016/j.jacc.2010.09.001]

4 **Pencina MJ**, D'Agostino RB, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the framingham heart study. *Circulation* 2009; **119**: 3078-3084 [PMID: 19506114 DOI: 10.1161/CIRCULATIONAHA.108.816694]

5 **Tahara N**, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, Hayabuchi N, Imaizumi T. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. *J Am Coll Cardiol* 2006; **48**: 1825-1831 [PMID: 17084257]

6 **Ichii M**, Ishimura E, Shima H, Ohno Y, Ochi A, Nakatani S, Tsuda A, Ehara S, Mori K, Fukumoto S, Naganuma T, Takemoto Y, Nakatani T, Inaba M. Quantitative analysis of abdominal aortic calcification in CKD patients without dialysis therapy by use of the Agatston score. *Kidney Blood Press Res* 2013; **38**: 196-204 [PMID: 24732137 DOI: 10.1159/000355768]

7 **Pen A**, Yam Y, Chen L, Dennie C, McPherson R, Chow BJ. Discordance between Framingham Risk Score and atherosclerotic plaque burden. *Eur Heart J* 2013; **34**: 1075-1082 [PMID: 23303659 DOI: 10.1093/eurheartj/ehs473]

8 **Morbelli S**, Fiz F, Piccardo A, Picori L, Massollo M, Pestarino E, Marini C, Cabria M, Democrito A, Cittadini G, Villavecchia G, Bruzzi P, Alavi A, Sambuceti G. Divergent determinants of 18F-NaF uptake and visible calcium deposition in large arteries: relationship with Framingham risk score. *Int J Cardiovasc Imaging* 2014; **30**: 439-447 [PMID: 24318613 DOI: 10.1007/s10554-013-0342-3]

9 **Canpolat U**, Yorgun H, Aytemir K, Hazrolan T, Kaya EB, Ateş AH, Dural M, Gürses KM, Sunman H, Tokgözoğlu L, Kabakç G, Oto A. Cardiovascular risk and coronary atherosclerotic plaques detected by multidetector computed tomography: Framingham and SCORE risk models underestimate coronary atherosclerosis in the symptomatic low-risk Turkish population. *Coron Artery Dis* 2012; **23**: 195-200 [PMID: 22327064 DOI: 10.1097/MCA.0b013e3283511608]

10 **Pugliese G**, Iacobini C, Blasetti Fantauzzi C, Menini S. The dark and bright side of atherosclerotic calcification. *Atherosclerosis* 2015; **238**: 220-230 [PMID: 25528431 DOI: 10.1016/j.atherosclerosis.2014]

11 **Derlin T**, Richter U, Bannas P, Begemann P, Buchert R, Mester J, Klutmann S. Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. *J Nucl Med* 2010; **51**: 862-865 [PMID: 20484438 DOI: 10.2967/jnumed.110.076471]

12 **Derlin T**, Wisotzki C, Richter U, Apostolova I, Bannas P, Weber C, Mester J, Klutmann S. In vivo imaging of mineral deposition in carotid plaque using 18F-sodium fluoride PET/CT: correlation with atherogenic risk factors. *J Nucl Med* 2011; **52**: 362-368 [PMID: 21321276 DOI: 10.2967/jnumed.110.081208]

13 **George RT**. 18F-sodium fluoride positron emission tomography: an in vivo window into coronary atherosclerotic plaque biology. *J Am Coll Cardiol* 2012; **59**: 1549-1550 [PMID: 22516445 DOI: 10.1016/j.jacc.2012.01.029]

14 **Dweck MR**, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, Richardson H, White A, McKillop G, van Beek EJ, Boon NA, Rudd JH, Newby DE. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. *J Am Coll Cardiol* 2012; **59**: 1539-1548 [PMID: 22516444 DOI: 10.1016/j.jacc.2011.12.037]

15 **Doherty TM**, Fitzpatrick LA, Inoue D, Qiao JH, Fishbein MC, Detrano RC, Shah PK, Rajavashisth TB. Molecular, endocrine, and genetic mechanisms of arterial calcification. *Endocr Rev* 2004; **25**: 629-672 [PMID: 15294885]

16 **Fiz F**, Morbelli S, Piccardo A, Bauckneht M, Ferrarazzo G, Pestarino E, Cabria M, Democrito A, Riondato M, Villavecchia G, Marini C, Sambuceti G. ¹⁸F-NaF Uptake by Atherosclerotic Plaque on PET/CT Imaging: Inverse Correlation Between Calcification Density and Mineral Metabolic Activity. *J Nucl Med* 2015; **56**: 1019-1023 [PMID: 25952737 DOI: 10.2967/jnumed.115.154229]

17 **Rosa GM**, Bauckneht M, Masoero G, Mach F, Quercioli A, Seitun S, Balbi M, Brunelli C, Parodi A, Nencioni A, Vuilleumier N, Montecucco F. The vulnerable coronary plaque: update on imaging technologies. *Thromb Haemost* 2013; **110**: 706-722 [PMID: 23803753 DOI: 10.1160/TH13-02-0121]

18 **Joshi NV**, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, Yeoh SE, Wallace W, Salter D, Fletcher AM, van Beek EJ, Flapan AD, Uren NG, Behan MW, Cruden NL, Mills NL, Fox KA, Rudd JH, Dweck MR, Newby DE. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. *Lancet* 2014; **383**: 705-713 [PMID: 24224999 DOI: 10.1016/S0140-6736(13)61754-7]

19 **Tison GH**, Guo M, Blaha MJ, McClelland RL, Allison MA, Szklo M, Wong ND, Blumenthal RS, Budoff MJ, Nasir K. Multisite extracoronary calcification indicates increased risk of coronary heart disease and all-cause mortality: The Multi-Ethnic Study of Atherosclerosis. *J Cardiovasc Comput Tomogr* 2015; **9**: 406-414 [PMID: 26043963 DOI: 10.1016/j.jcct.2015.03.012]

20 **Adar A**, Erkan H, Gokdeniz T, Karadeniz A, Cavusoglu IG, Onalan O. Aortic arch calcification is strongly associated with coronary artery calcification. *Vasa* 2015; **44**: 106-114 [PMID: 25698388 DOI: 10.1024/0301-1526/a000415]

21 **Brodov Y**, Gransar H, Rozanski A, Hayes SW, Friedman JD, Thomson LE, Dey D, Slomka PJ, Min JK, Shaw LJ, Shah PK, Germano G, Berman DS. Extensive thoracic aortic calcification is an independent predictor of development of coronary artery calcium among individuals with coronary artery calcium score of zero. *Atherosclerosis* 2015; **238**: 4-8 [PMID: 25461732 DOI: 10.1016/j.atherosclerosis.2014.10.100]

22 **Beheshti M**, Saboury B, Mehta NN, Torigian DA, Werner T, Mohler E, Wilensky R, Newberg AB, Basu S, Langsteger W, Alavi A. Detection and global quantification of cardiovascular molecular calcification by fluoro18-fluoride positron emission tomography/computed tomography--a novel concept. *Hell J Nucl Med* 2011; **14**: 114-120 [PMID: 21761011]

23 **Hao L**, Hao J, Fang W, Han C, Zhang K, Wang X. Dual isotope simultaneous imaging to evaluate the effects of intracoronary bone marrow-derived mesenchymal stem cells on perfusion and metabolism in canines with acute myocardial infarction. *Biomed Rep* 2015; **3**: 447-452 [PMID: 26171146]

24 **Rogers IS,** Nasir K, Figueroa AL, Cury RC, Hoffmann U, Vermylen DA, Brady TJ, Tawakol A. (18)F-NaF PET Imaging of Early Coronary Artery Calcification. *JACC Cardiovasc Imaging* 2015; Epub ahead of print [PMID: 26189122 DOI: 10.1016/j.jcmg.2015.02.026]

25 **Rogers IS**, Nasir K, Figueroa AL, Cury RC, Hoffmann U, Vermylen DA, Brady TJ, Tawakol A. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. *JACC Cardiovasc Imaging* 2010; **3**: 388-397 [PMID: 20394901 DOI: 10.1016/j.jcmg.2010.01.004]

26 **Johnson T,** Ding H, Lipinski J, Molloi S. SU-E-I-25: Quantification of Coronary Artery Cross-Sectional Area in CT Angiography Using Integrated Density: A Simulation Study. *Med Phys* 2015; **42**: 3247 [DOI: 10.1118/1.4924022]

27 **Slomka PJ**, Pan T, Berman DS, Germano G. Advances in SPECT and PET Hardware. *Prog Cardiovasc Dis* 2015; **57**: 566-578 [PMID: 25721706 DOI: 10.1016/j.pcad.2015.02.002]

28 **Craiem D**, Chironi G, Casciaro ME, Graf S, Simon A. Calcifications of the thoracic aorta on extended non-contrast-enhanced cardiac CT. *PLoS One* 2014; **9**: e109584 [PMID: 25302677 DOI: 10.1371/journal.pone.0109584]

29 **Shahcheraghi N**, Dwyer HA, Cheer AY, Barakat AI, Rutaganira T. Unsteady and three-dimensional simulation of blood flow in the human aortic arch. *J Biomech Eng* 2002; **124**: 378-387 [PMID: 12188204]

30 **Irkle A**, Vesey AT, Lewis DY, Skepper JN, Bird JL, Dweck MR, Joshi FR, Gallagher FA, Warburton EA, Bennet MR, Brindle KM, Newby DE, Rudd JH, Davenport AP. Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography. *Nat Commun* 2015; **6:** 7495 [PMID: 26151378 DOI: 10.1038/ncomms8495]

**P-Reviewer:** Petix NR, Said SAM **S-Editor:** Qi Y **L-Editor: E-Editor:**



**Figure 1 Volume of interest placement and 3D rendering of the vascular segments and of the myocardium.** Volumes of interest were constructed by placing sequential region of interest on the transaxial CT slices, carefully adjusting the edges so as to include the entire vessel/myocardium (top panels). The figure depicts the 3D rendering of the three aortic segments and of the heart (bottom panels).



**Figure 2 Target-to-background ratio differences in** **cardiovascular risk classes.** The figure highlights the average target-to-background ratio (TBR) values for the whole thoracic aorta (top left), the myocardium (top right) and the three different thoracic aorta segments (bottom). a*P* < 0.05; b*P* < 0.01; c*P* < 0.001.



**Figure 3 Correlation between fluoride uptake and clinical cardiovascular risk.** A strong correlation was noted between thoracic aorta NaF uptake and cardiovascular risk (CVR), but also between aortic and myocardial uptake (top panels). Among the thoracic aorta subsegments, descending aorta provided the strongest correlation (bottom panels).

**Table 1 Patients' characteristics**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Patients number** | **Mean age** | **Gender m/f** | **Systolic bp** | **Bp treatment (Yes/No)** | **Smoke** | **Diabetes** | **BMI** | **Mean CVR** |  **Whole thoracic aorta TBR** | **NGCMS** |
| Low CVR | 22 | 58.3 ± 8.2  | 7/15 | 114 ± 5 | 2/20 | 1/21 | 2/22 | 24 ± 1 | 6.6 ± 2.3% | 1.14 ± 0.34  | 104 ± 46 |
| Medium CVR | 36 | 65 ± 9.5 | 10/26 | 123 ± 6 | 12/24 | 14/22 | 5/31 | 25 ± 3 | 14.3 ± 3 % | 1.4 ± 0.4  | 62 ± 21 |
| High CVR | 20 | 65 ± 9.1  | 10/10 | 128 ± 11 | 8/12 | 19/1 | 15/5 | 27 ± 2 | 29 ± 2.4%  | 1.8 ± 0.75 | 43 ± 17  |

CVR: Cardiovascular risk; TBR: Target-to-background ratio; NGMCS: Normalized Global Molecular Calcification Score.

**Table 2 Target-to-background ratio differences in risk group (*P* value)**

|  |  |  |  |
| --- | --- | --- | --- |
| 　 | **High** | **Medium** | **Low** |
| Thoracic aorta |  |  |  |
| High | - | 0.031 | 0.002 |
| Medium | 0.031 | - | 0.023 |
| Low | 0.002 | 0.023 | - |
| 　Ascending aorta |  |  |  |
| High | - | 0.085 | 0.013 |
| Medium | 0.085 | - | 0.056 |
| Low | 0.013 | 0.056 | - |
| 　Aortic arch |  |  |  |
| High | - | 0.066 | 0.007 |
| Medium | 0.066 | - | 0.033 |
| Low | 0.007 | 0.033 | - |
| 　Descending aorta |  |  |  |
| High | - | 0.012 | 0.001 |
| Medium | 0.012 | - | 0.018 |
| Low | 0.001 | 0.018 | - |
| 　Normalized global molecular calc. Score |  |  |  |
| High | - | 0.00015 | 0.00001 |
| Medium | 0.00015 | - | 0.00280 |
| Low | 0.00001 | 0.00280 | - |

**Table 3 Correlation between aortic uptake, cardiovascular risk and Normalized Global Molecular Calcification Score**

|  |  |  |
| --- | --- | --- |
| **Segment TBR** | **CVR** | **NGMCS** |
| 　 | R2 | R | R2 | R |
| Ascending | 0.52 | 0.72 | 0.27 | 0.52 |
| Arch | 0.48 | 0.70 | 0.35 | 0.59 |
| Descending | 0.62 | 0.79 | 0.52 | 0.72 |
| All segments | 0.67 | 0.82 | 0.45 | 0.67 |

CVR: Cardiovascular risk; TBR: Target-to-background ratio; NGMCS: Normalized Global Molecular Calcification Score.